The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.

The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.